Loading
Coverage gauges say whether each record is complete. This page asks the other question: of everything that exists, how much is here? Each row sets an OnCo count against a sourced count of the world, on the same scope, and names what is missing.
Across the 15 scopes with a public list, OnCo holds 2,233 of 2,628 listed items (85%). Denominators come from src/data/universe.ts; the lists are refreshed weekly by npm run fetch:universe into src/data/universe-lists/, and the matching lives in src/lib/completeness.ts. “About” marks a denominator that is a round figure, a search hit count, or depends on name matching. A low number is not a failing: OnCo is a curated map, not a registry, and some scopes (every interventional cancer trial, every dictionary term) are shown for scale.
Each list is the source's items that match nothing in OnCo by name, alias, identifier or website. Matching is exact after normalisation, so a listed item can occasionally be present under a name the matcher does not know; if so, add the alias to the record instead.
World: Every link in the A to Z list that points to a drug page; brand-name entries that point to the same page as the generic are folded into one item, so the total is distinct drug pages (single agents and named combinations). NCI: A to Z List of Cancer Drugs, checked on 2026-09-30.
OnCo: Products in OnCo matched to an NCI entry by generic name, brand name, alias or code.
World: Every entry in the 'Find a cancer type' A to Z list (distinct names; several names can share one NCI page). NCI: A to Z List of Cancer Types, checked on 2026-09-30.
OnCo: Cancers in OnCo matched to an NCI entry by name or alias (UK and US spellings treated as equal).
Every listed item is in OnCo.
World: The 36 cancer sites GLOBOCAN 2022 estimates (codes 1 to 36 from the GCO metadata API; the aggregate codes 37 to 41 are excluded). IARC Global Cancer Observatory: GLOBOCAN 2022, checked on 2026-09-30.
OnCo: GLOBOCAN sites that at least one OnCo cancer page maps to (src/data/globocan-map.ts).
Every listed item is in OnCo.
World: ChEMBL API: drug indications with max_phase_for_ind=4 (approved) whose MeSH heading contains one of Neoplasm, Carcinoma, Leukemia, Lymphoma, Myeloma, Melanoma, Sarcoma, Glioma, Glioblastoma, Tumor, Cancer, Mesothelioma, Blastoma, Adenoma; the distinct parent molecules' mechanisms of action; the distinct targets of those mechanisms, with gene symbols from the target components. Includes non-protein targets (DNA, tubulin) and drugs whose oncology indication is supportive. ChEMBL: mechanism targets of approved drugs with an oncology indication, checked on 2026-09-30.
OnCo: ChEMBL targets whose gene symbol matches an OnCo target's symbol, name or alias.
World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-30.
OnCo: OnCo trials with an NCT id.
The source publishes a total, not a list, so the gap (91,556) cannot be itemised here. Propose an addition through the new-object form.
World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-30.
OnCo: OnCo trials with an NCT id and phase 3 or 2/3.
The source publishes a total, not a list, so the gap (8,673) cannot be itemised here. Propose an addition through the new-object form.
World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-30.
OnCo: OnCo trials with an NCT id whose status is recruiting or active.
The source publishes a total, not a list, so the gap (10,314) cannot be itemised here. Propose an addition through the new-object form.
World: ClinicalTrials.gov API v2 with query.cond=cancer and countTotal=true: interventional studies; of those, phase 3; of those, recruiting. Sponsors: distinct lead sponsor names (class INDUSTRY) across all phase 3 interventional cancer studies, so subsidiaries and name variants count separately. ClinicalTrials.gov: interventional studies, condition 'cancer', checked on 2026-09-30.
OnCo: Sponsor names matched to an OnCo company by name or alias after removing corporate suffixes; subsidiaries listed under their own name count as separate sponsors.
The full list is in src/data/universe-lists/ctgov-oncology.json.
World: Sponsor named in brackets in each FDA OCE oncology approval notification on the current page, grouped after removing corporate suffixes. Covers the notifications the page still lists (see window), so it is a floor for 'companies with a recent FDA oncology approval'. FDA Oncology Center of Excellence: approval notifications, checked on 2026-09-30.
OnCo: Sponsors named in FDA OCE notifications matched to an OnCo company by name or alias.
World: Every centre profile linked from the NCI 'Find a Cancer Center' page (one entry per centre, even when a centre is listed in several states); the website comes from each profile page. NCI: Find a Cancer Center, checked on 2026-09-30.
OnCo: NCI centres matched to an OnCo institution by website domain or name.
Every listed item is in OnCo.
World: Every member profile on the Organisation of European Cancer Institutes member list (full, associate and corresponding members), with the leaders named on each profile. OECI: Member Profiles, checked on 2026-09-30.
OnCo: OECI members matched to an OnCo institution by website domain or name.
World: The companies array embedded in the Even One Ventures home page (name, website and sector tag), read weekly so new portfolio companies surface on /completeness/. Even One Ventures: portfolio, checked on 2026-09-30.
OnCo: Portfolio companies matched to an OnCo company by website domain or name; refreshed weekly so new companies surface here.
World: The numbered list of Cancer Alliances under 'Map of Cancer Alliances in England' on the NHS England page. NHS England: Cancer Alliances, checked on 2026-09-16.
OnCo: Cancer Alliances matched to an OnCo institution by website domain or name.
Every listed item is in OnCo.
World: The member-organisation count stated on the UICC membership page (a round figure published by UICC, so approximate). UICC: Membership, checked on 2026-09-30.
OnCo: All institutions in OnCo (membership is not verified per record, so this is an upper bound on coverage).
The source publishes a total, not a list, so the gap (374) cannot be itemised here. Propose an addition through the new-object form.
World: The first person named under the leadership heading of each OECI member profile (director, CEO or equivalent); members with no leader listed are excluded. OECI: Member Profiles, checked on 2026-09-30.
OnCo: Leaders matched to an OnCo person by name after removing titles.
World: One director per NCI-designated centre; the NCI profile pages do not list names, so only the count is external. NCI: Find a Cancer Center, checked on 2026-09-30.
OnCo: People in OnCo whose primary institution is NCI-designated and whose role starts with Director.
The source publishes a total, not a list, so the gap (0) cannot be itemised here. Propose an addition through the new-object form.
World: Maps listed under 'Cancer: overview' and 'Cancer: specific types' in KEGG BRITE br08901 (pathway map hierarchy), via the KEGG REST API. KEGG PATHWAY: Human Diseases, Cancer, checked on 2026-09-30.
OnCo: KEGG maps mapped by hand to at least one OnCo pathway page (src/lib/completeness.ts).
Every listed item is in OnCo.
World: The eight hallmarks and two enabling characteristics of Hanahan and Weinberg (2011) plus the two emerging hallmarks and two enabling characteristics proposed in the 2022 update: fourteen in total. Each is mapped by hand to the OnCo pathway pages that explain it; a hallmark counts as covered when at least one mapped page exists. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery 2022;12(1):31-46, checked on 2026-09-10.
OnCo: Hallmarks with at least one mapped OnCo pathway page.
Every listed item is in OnCo.
World: Reactome ContentService search for 'cancer', species Homo sapiens, type Pathway; the number of matching pathways. A text search, so approximate. Reactome: pathways matching 'cancer' (human), checked on 2026-09-30.
OnCo: All pathway pages in OnCo (a scale comparison, not a name match).
The source publishes a total, not a list, so the gap (383) cannot be itemised here. Propose an addition through the new-object form.
World: E-utilities esearch on the NLM Catalog for 'neoplasms[st] AND currentlyindexed[All]' (the MEDLINE broad subject term for cancer journals), then esummary for titles and ISSNs. NLM Catalog: journals currently indexed for MEDLINE, broad subject term Neoplasms, checked on 2026-09-30.
OnCo: NLM journals matched to an OnCo journal by ISSN, title or MEDLINE abbreviation.
Every listed item is in OnCo.
World: OpenAlex works filtered to primary_topic.subfield = Oncology (2730), sorted by citation count, first 100. OpenAlex: most-cited works, subfield Oncology, checked on 2026-09-30.
OnCo: Works matched to an OnCo key paper by DOI.
World: The term count returned by the NCI glossary API for the English patient dictionary. NCI Dictionary of Cancer Terms, checked on 2026-09-30.
OnCo: All glossary terms in OnCo (a scale comparison, not a term match).
The source publishes a total, not a list, so the gap (8,189) cannot be itemised here. Propose an addition through the new-object form.
These are OnCo's own taxonomy. There is no external list of fronts, technologies, pairings, roadmaps, ideas, bottlenecks or collections to count against, so no completeness is claimed; the number is the corpus count.
See also the corpus health gauges (record-level completeness), gaps to fill, and open data sources.